Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Emotional response to murderous apathy?
Jarnail Singh, a Sikh journalist who acquired a celebrity status after the shoe-throwing incident at a press conference addressed by Home Minister P Chidambaram on April 7, 2009, has exercised unusual caution while narrating the incident that made him a hero for large sections of the Sikh community. It is ironic because the “heroism” for which he was hailed by many Sikh bodies, including the Sikh Gurdwara Prabandhak Committee, was clearly missing when it came to narrating the events that led to the infamous shoe-throwing incident.

Mahindra Satyam down 7% on L&T's stake sale
Mahindra Satyam slipped to a low of Rs 109 and finally ended at Rs 110, down around 7%. The counter witnessed trades of 46.44 million shares on the BSE as compared to the two-week daily average traded volumes of 7.23 million shares.

News of the day

Government sets up schedule to provide relief to accident victims
The government on Thursday set a schedule to examine the problems ailing the insurance sector in the field of accident insurance. This comes close on the heels of the Supreme Court suggesting the government to create a special fund for compensating accident victims by charging a cess on sale of petrol or a one-time premium on sale of new motor vehicles.
Management

Piramal Life starts trial of new diabetes drug

Piramal Life Sciences has commenced phase I trial of a new experimental drug molecule P2202 for diabetes metabolic syndrome in Canada. P2202 is the second compound from Eli Lilly and is part of the collaborative agreement between two companies and is being developed for diabetes metabolic syndrome. - Dr Reddy"s to invest Rs 750 crore in two SEZs - Rising rupee could help Ranbaxy negate loss in Q2 - Piramal Life Sciences to invest Rs 200 cr in R&D - Novartis open offer to begin on May 20 - Ranbaxy seeks govt nod for excess pay to directors - Piramal Life up on clinical-trial nod The metabolic syndrome is characterised by a group of metabolic risk factors such as abdominal obesity, blood fat disorders that foster plaque build ups in artery walls, elevated blood pressure, insulin resistance and pro-inflammatory state. People with metabolic syndrome are at increased risk of coronary heart disease, stroke and type 2 diabetes. P2202 is being developed for the treatment of metabolic disorders. Piramal Life Sciences had submitted the clinical trial application for P2202 to Health Canada, Canada"s regulatory authority. This body has approved company"s application to initiate phase I study of P2202.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009